cardiovascular
Novartis’ Entresto tops enalapril in stabilised heart failure patients
November 13, 2018Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma
Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …
AZ’s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study
November 12, 2018Research and Development, Sales and Marketing AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) …
Researchers design new class of drugs to counter cardiovascular disease
August 14, 2018Manufacturing and Production TMAO, cardiovascular, gut microbe, heart attack, research
Cleveland Clinic researchers have designed a potential new class of drugs that may reduce the risk of cardiovascular disease by …
The new and improved Spring 2018 edition of Pharmafile is available to read online now!
May 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile
The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …
Google develops AI to predict cardiovascular risk
February 21, 2018Research and Development AI, Verily Life Sciences, biotech, cardiovascular, drugs, google, pharma, pharmaceutical
Google and Verily Life Sciences, a subsidiary within Alphabet, focused on developing health-tech, have revealed the fruits of a combined …
Novartis targets specific patient population with strong Ilaris Phase 3 data
November 14, 2017Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma
Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …
AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals
September 7, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial
AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …
Extended use of AstraZeneca’s Brilinta reduces cardiovascular death risk
August 24, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, life sciences, pharma, pharmaceutical
New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk …
Mending broken hearts with an injectable patch
August 16, 2017Research and Development biotech, cardiovascular, drugs, heart disease, pharma, pharmaceutical
A team of researchers from the University of Toronto have confronted a problem that had previously had no solution – …
Heart failure mortality rates fall across England and Wales, national audit finds
August 11, 2017Medical Communications, Research and Development cardiovascular, heart, heart disease, life sciences, pharma, pharmaceutical
Great news in the cardiovascular space as results from the National Heart Failure Audit indicate that better treatment has led …
Heart scan offers possibility of non-invasive diagnosis
July 13, 2017Medical Communications, Research and Development biotech, cardiovascular, drugs, heart, heart scan, pharma, pharmaceutical
Scientists from the University of Oxford have developed a heart scan that can identify inflammation around arteries that can suggest …
Novartis and Ionis enter $1bn cardiovascular drug deal
January 6, 2017Medical Communications, Research and Development, Sales and Marketing Akcea, Akcea Therapeutics, Ionis, Ionis Pharmaceuticals, cardiovascular
Ionis Pharmaceuticals and one of its wholly-owned subsidiaries Akcea Therapeutics have entered into a partnership with Novartis worth potentially more …
Sanofi, Regeneron say cholesterol drug Praluent approved in Japan
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt
Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …
Eli Lilly says FDA panel backs approval of Jardiance for cardiovascular indication
June 30, 2016Research and Development, Sales and Marketing Eli Lilly, cardiovascular, diabetes, jardiance
US drugmaker Eli Lilly (NYSE: LLY) said a US regulatory panel has backed its Jardiance (empagliflozin) for reducing cardiovascular death …
Chiesi set to acquire Medicine Co cardiovascular assets, say reports
May 9, 2016Sales and Marketing Chiesi, assets, cardiovascular, medicine co
Italian pharmaceutical company Chiesi are set to expand their global footprint as it nears an agreement to acquire Medicines Co’s …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
